Arrhythmias & electrophysiology
Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing
Authors' conclusion
These results show that the AtaCor parasternal EV-ICD system is feasible and safe, with high defibrillation efficacy in induced ventricular arrhythmias and a low occurrence of major complications within 30 days.
Study context
- Population
- Patients with a class I or IIa indication for ICD therapy
- Participants
- 19 patients
- Outcome
- Acute defibrillation success and freedom from major complications
- Follow-up
- 30 days
Main finding
As reported in the abstract
Acute defibrillation success
Defibrillation testing successful (17 of 18 tested)
94%
Lead successfully deployed (19 of 19 attempted implants)
100%
Further findings
| Outcome | Values |
|---|---|
| Successful lead deployment | Parasternal EV-ICD 100% |
| Intraprocedural pacing capture (dedicated bipolar pacing vector) | Parasternal EV-ICD 100% |
- Successful lead deployment: 19 of 19 attempted implant procedures
- Intraprocedural pacing capture (dedicated bipolar pacing vector): 17 of 17 chronically implanted subjects
Intraprocedural pacing capture (dedicated bipolar pacing vector)
- Pacing well tolerated at predischarge visit
Safety
Freedom from major complications · 30 days
- Freedom from major complications
- 95% (95% CI 74% to >99%)
Original publication
Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. Heart Rhythm. Published 15 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →